DP
SABS icon

Diadema Partners’s SAB Biotherapeutics SABS Stock Holding History

Diadema Partners’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$114K – 146
2024
Q4 		$114K Buy
+30,000
New +$98.5K 0.05% 92

Other funds holding SABS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOS
Silver Oak Securities Jackson, Tennessee $1.37B AUM 20.67% 1-Year Est. Return
Kovitz Investment Group Partners
Kovitz Investment Group Partners Chicago, Illinois $4.31B AUM 20.41% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Diadema Partners's SABS Position: Q1 2025 in Review

Diadema Partners sold out of SAB Biotherapeutics (SABS) in Q1 2025, closing a stake of 30,000 shares — an estimated $114K sold.

Diadema Partners first reported a position in SABS in Q4 2024 and held it in 1 quarter. The position peaked at $114K in Q4 2024. 26 funds tracked by Wall St. Rank hold SABS as of Q1 2025.

  • Diadema Partners reported no remaining SAB Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Diadema Partners sold 30,000 SAB Biotherapeutics shares in Q1 2025, an estimated $114K.
  • Diadema Partners first reported a position in SAB Biotherapeutics in Q4 2024 and held it in 1 quarter.
  • Diadema Partners's SAB Biotherapeutics position peaked at $114K in Q4 2024.
  • 26 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.